Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium,…
Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with…
Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line…
In this weeks video, Dr. Brian G.M. Durie talks about ways myeloma patients, caregivers, or family members can give back…
In this weeks video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and…
In this weeks video, Dr. Brian G.M. Durie discusses the Black Swan Research Initiatives 3 Cure trials, which use new…
In this weeks video, Dr. Brian G.M. Durie details the results of the STORM 2b trial, which uses selinexor in…
In this weeks video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma…
In this weeks video, Dr. Brian G.M. Durie comments on why it is not necessary for multiple myeloma patients to…
In this video, Dr. Brian G.M. Durie explains how researchers are studying minimal residual disease (MRD) testing further to better…
In this video, Dr. Brian G.M. Durie explains that active myeloma is diagnosed if a patient has CRAB features and…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Xofigo Program. At ESMO Oncology Conference -…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Stivarga Program. At ESMO Oncology Conference -…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Regorafenib Program. At ESMO Oncology Conference -…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Copanlisib Program. At ESMO Oncology Conference -…
CRISTIANE DECAT BERGEROT, PhD PSYCHOLOGIST, POSTDOCTORAL FELLOW CITY OF HOPE COMPREHENSIVE CANCER CENTER discusses THE IMPACT OF THE PSYCHOSOCIAL MILIEU…
Eric A. Singer, MD, MA, MS, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Section of Urologic…
Bellinda King-Kallimanis, PhD of U.S. Food and Drug Administration, Maryland (FDA ) discusses Incorporating Relevant and Meaningful ?Patient-Reported Outcomes in…
André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department – Hospital São Lucas da PUCRS/…
Samra Turajlic BA, MBBS, MRCP, PhD, Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust, London Cancer Research UK Clinician Scientist,…
E. Jason Abel MD, FACS University of Wisconsin discusses Cytoreductive nephrectomy Placing recent clinical trials in context at the Seventeenth…
Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage…
Earn CME: https://naccme.com/program/7309 In this Key Insights activity, Drs. Morton Coleman and John P. Leonard discuss highlights in lymphoma from…
Earn CME: https://naccme.com/program/7308 In this Key Insights activity, Drs. Morton Coleman and Richard R. Furman discuss CLL-related highlights from Lymphoma…
Earn CME: https://naccme.com/program/7307 In this Key Insights activity, Drs. Morton Coleman and Ruben Niesvizky discuss myeloma presentation highlights from Lymphoma…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Drs. Langer, Aggarwal, Bazhenova, and…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Lyudmila Bazhenova discusses EGFR…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Charu Aggarwal discusses frontline…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Helen Ross discusses the…
Michael A.S. Jewett DEPARTMENT OF SURGICAL ONCOLOGY PRINCESS MARGARET CANCER CENTRE DIVISION OF UROLOGY THE UNIVERSITY OF TORONTO discusses Heterogeneity…
Kimberly Allman, MSN, CNP Cleveland Clinic Taussig Cancer Institute discusses Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint…
Ritesh Kotecha discusses Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma at the Seventeenth…
Neeraj Agarwal Huntsman Cancer Center discusses Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab:?Results of the dose-escalation stage…
Andrey Soares Medical Oncologist Centro Paulista de Oncologia and Hospital Israelita Albert Einstein SPChair LACOG GU gives an UPDATES LATIN…
Rodolfo Borges dos Reis, MD, PhD Uro-oncology Ribeirao Preto Medical School discusses LARCG Latin American Renal Cancer Group at the…
Alberto Diaz de Leon M.D. discusses Whole Body MRI for Detection of Renal Cell Carcinoma Osseous Metastases at the Seventeenth…
Abhishek A. Chakraborty Instructor in Medicine Department of Medical Oncology Laboratory of William Kaelin Dana-Farber Cancer Institute Harvard Medical School…
Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess Medical Center Research Fellow, Dana Farber…
A Ari Hakimi MD Assistant Member, Department of Surgery, Urology Service Member, Immunogenomics and Precision Oncology Platform discusses the Novel…
Toni K. Choueiri, MD Director, Lank Center for Genitourinary Oncology Department of Medical Oncology Dana-Farber Cancer Institute discusses Neovax: From…
Thai H. Ho, MD, PhD Mayo Clinic Arizona discusses Targeting Epigenetics and Chromatin Remodeling Genes From the Seventeenth International Kidney…
Thomas Powles Director of Barts Cancer Centre discusses The next therapeutic targets: TGFbeta From the Seventeenth International Kidney Cancer International…
Abhishek Tripathi MD Assistant Professor of Medicine University of Oklahoma Stephenson Cancer Center discusses Adenosine Pathway Inhibitors From the Seventeenth…
Ranjit S. Bindra, M.D., Ph.D. Associate Professor Departments of Therapeutic Radiology and Experimental Pathology Yale Cancer Center discusses Exploiting oncometabolite-induced…
Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses…
Suzanne Cole, MD FACP Medical Director, Community Cancer Clinic Richardson Plano UT Southwestern Medical Center discusses Engaging Clinical Trialists in…
Robert G. Uzzo, M.D. Willing G. Pepper Chairman of Surgery Fox Chase Cancer Center Temple University School of Medicine Chair,…
Hyung L. Kim, M.D. Director, Academic Urology Programs Cedars Sinai Medical Center discusses What is the Next Cytoreductive Surgical Trial?…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology MD Anderson Cancer Center discusses Combination…
Phillip M. Pierorazio, MD Associate Professor of Urology and Oncology Brady Urological Institute, Department of Urology? Johns Hopkins Medicine, Baltimore,…
Dr. Andrew W. Silagy Urologic Oncology Research Fellow Memorial Sloan Kettering Cancer Center discusses An Evaluation of the Role of…
Nizar M. Tannir University of Texas MD Anderson Cancer Center, Houston, TX, USA discusses CheckMate 214 Retrospective Analyses From the…
Nieves Martinez Chanza Department of Oncology, Jules-Bordet Institute, Free University of Brussels (Belgium) discusses Safety and efficacy of checkpoint inhibitors…
Tian Zhang, MD Assistant Professor of Medicine Duke Cancer Institute discusses PDIGREE From the Seventeenth International Kidney Cancer International Symposium…
Thomas Powles Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, UK…
Rana R. McKay, MD Assistant Professor of Medicine UC San Diego discusses Rationally Targeting the Bone with Radium Plus Cabozantinib…
Matt Campbell MD Assistant Professor GU Medical Oncology UT MD Anderson Cancer Center discusses Ongoing Clinical Trial Update: A Pilot…
Moshe C. Ornstein MD MA, Laura S. Wood RN MSN OCN, Kimberly Allman MSN CNP, Allison Martin PA-C Timothy Gilligan…
Hans Hammers MD, PhD Associate Professor of Internal Medicine in the Division of Hematology-Oncology at UT Southwestern Medical Center discusses…
Charles G. Drake MD / PhD Director GU Medical Oncology Co-Director: Immunotherapy Program Associate Director for Clinical Research Professor of…
Primo N Lara, Jr., MD Director, University of California Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean…
Michael B. Atkins, M.D. William M. Scholl Professor and Vice Chair Department of Oncology Deputy Director Georgetown-Lombardi Comprehensive Cancer Center…
Ewelina Morawa, MD Executive Medical Director CRISPR Therapeutics discusses Allogeneic Anti-CD70 CAR T Cells ?for Renal Cell Carcinoma From the…
Steven L. Chang, MD, MS Assistant Professor of Surgery, Harvard Medical School Surgical Oncologist, Dana-Farber Cancer Institute Associate Surgeon, Division…
Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Enucleation of Renal Mass:…
Gopal N. Gupta, MD, FACS Associate Professor Departments of Urology, Surgery and Radiology Cardinal Bernardin Cancer Center Loyola University Health…
Steven S. Raman, MD FSAR FSIR Professor of Radiology, Urology and Surgery Division of Abdominal Imaging & Intervention Departments of…
John Leppert, MD MS Associate Professor Stanford University Director of Urologic Oncology, VA Palo Alto discusses Overdiagnosis and the Harms…
Timothy McClure, MD Assistant Professor of Urology Assistant Professor of Interventional Radiology Weill Cornell Medicine discusses Emerging Ablative Technologies -…
Jaime Landman Professor of Urology and Radiology Chairman, Department of Urology UCI discusses Renal mass biopsy in 2018: When, where…
David Braun, MD, PhD, Dana-Farber Cancer Institute discusses Single Cell RNA-Sequencing in RCC from the Seventeenth International Kidney Cancer International…
Dr. Lisa Derosa, MD PhD Candidate Immunoncology – Pr. L. Zitvogel discusses The impact of the stool microbiome in RCC…
James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, UT Southwestern Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair…
James J. Hsieh MD PhD Professor, Molecular Oncology, Siteman Cancer Center, Washington University in St. Louis discusses RCC Profiling from…
Neeraj Agarwal, MD Professor of Medicine Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research Co-Leader, HCI Experimental Therapeutics…
Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Larotrectinib Program. At ESMO Oncology Conference -…
Do-Youn Oh, M.D., of Seoul National University Hospital discusses Treating Advanced Biliary Cancer: M7824 Data. At ESMO Oncology Conference -…
Do-Youn Oh, M.D., of Seoul National University Hospital discusses Pembrolizumab Monotherapy In Biliary Cancer. At ESMO Oncology Conference – Munich,…
Do-Youn Oh, M.D., of Seoul National University Hospital discusses Future Of Biliary Cancer Treatment. At ESMO Oncology Conference – Munich,…
Do-Youn Oh, M.D., of Seoul National University Hospital discusses Future Of Biliary Cancer Treatment. At ESMO Oncology Conference – Munich,…
Sanjay Popat, M.D., of The Royal Marsden Hospital Discusses ALTA-1L Trial CNS Efficacy. At ESMO Oncology Conference – Munich, Germany…
Scott Tagawa, M.D., of Weill Cornell Medicine discusses PSMA-617 Study. At ESMO Oncology Conference – Munich, Germany On October 19,…
Scott Tagawa, M.D., Of Weill Cornell Medicine discusses Availability Of PSMA-617 Radionuclide Therapy. At ESMO Oncology Conference – Munich, Germany…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Whats on The Horizon For Bayer Pharmaceuticals. At…
David Peereboom, M.D., Cleveland Clinic Discusses The Future Of Treating Glioblastoma. At ESMO Oncology Conference – Munich, Germany On October…
Dra. Cristina Gutierrez talks about selecting the best doctor and communicating with the physician in treating prostate cancer
SpaceOAR gel and other preventive protocols to minimize side effects for radiation therapy for prostate cancer as detailed by Dra.…
The benefits of hormonal therapy in conjunction with radiation treatment as discussed by Dra. Cristina Gutierrez
Dr. Cristina Gutierrez discusses treatment option decisions for prostate cancer
Pascal Besman Chief Operating Officer at PharmaMar discusses Emerging New Agents In SCLC. At ESMO Oncology Conference – Munich, Germany…
Hope Rugo, M.D., University Of California San Francisco discusses EMBRACA Trial, Sensoring Process, QOL. At ESMO Oncology Conference – Munich,…
Hope Rugo, M.D., University Of California San Francisco discusses Talazoparib First Line Treatment. At ESMO Oncology Conference – Munich, Germany…
Hope Rugo, M.D., University Of California San Francisco discusses IMpassion130, Solar-1 Trial Data. At ESMO Oncology Conference – Munich, Germany…
Hope Rugo, M.D., University Of California San Francisco discusses EMBRACA Trial, FDA Approval Of Talazoparib. At ESMO Oncology Conference -…
Hope Rugo, M.D., University Of California San Francisco discusses Data On Neoadjuvant Talazoparib. At ESMO Oncology Conference – Munich, Germany…
Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON3 Randomized Study. At ESMO Oncology Conference – Munich, Germany On October…
Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON2 Trial, Rucaparib PARP Inhibitor Data. At ESMO Oncology Conference – Munich,…
Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON2 Trial Results. At ESMO Oncology Conference – Munich, Germany On October…
David Peereboom, M.D., Cleveland Clinic Discusses SL-701 Availability. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.
David Peereboom, M.D., Cleveland Clinic Discusses New Plans With SL-701 Drug. At ESMO Oncology Conference – Munich, Germany On October…
David Peereboom, M.D., Cleveland Clinic Discusses How SL-701 Was Generated. At ESMO Oncology Conference – Munich, Germany On October 19,…
Pascal Besman Chief Operating Officer at PharmaMar discusses Whats On Deck For Lurbinectedin. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses Upcoming SCLC Data. At ESMO Oncology Conference – Munich, Germany On October…
Pascal Besman Chief Operating Officer at PharmaMar discusses Progress In SCLC Vs. NSCLC. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses Lurbinectedin Data Presented This Year. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses IO Likely In 1st Line SCLC. At ESMO Oncology Conference – Munich,…
Pascal Besman Chief Operating Officer at PharmaMar discusses Current Standard Of Care In SCLC. At ESMO Oncology Conference – Munich,…
Byoung Chul Cho, M.D., Yonsei Cancer Center discusses Efficacy & Safety Of M7824. At ESMO Oncology Conference – Munich, Germany…
Byoung Chul Cho, M.D., Yonsei Cancer Center discusses NSCLC With M7824 Second Line Therapy. At ESMO Oncology Conference – Munich,…
Byoung Chul Cho, M.D., Yonsei Cancer Center discusses What To Expect In NSCLC & HN Cancer For 2019. At ESMO…
Michael Davidson, M.D., Royal Marsden Hospital, discusses Gastric & Esophageal Cancer: Treating Female Patients. At ESMO Oncology Conference – Munich,…
Michael Davidson, M.D., Royal Marsden Hospital, discusses Gender Differences: Gastric & Esophageal Cancer Treatment. At ESMO Oncology Conference – Munich,…
Scott Fields, SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Larotrectinib, Xofigo, Copanlisib, & Regorafenib Research. At ESMO Oncology…
Scott Fields, SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Treatment With Xofigo, Abiraterone, & Copanlisib. At ESMO Oncology…
Thomas Helleday, Phd, Helleday Laboratory, Discusses Using Mutational Signatures To Tailor New Treatments. At ESMO Oncology Conference – Munich, Germany…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines…
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states…
David Peereboom, MD, Cleveland Clinic Discusses SL-701 Phase Two Trial Study Results. At ESMO Oncology Conference – Munich, Germany On…
Diana Roettger, PhD, Head of Scientific and Medical Affairs and Imaging Clinical Research Expert at IAG Discusses Radiological Phenotyping For…
Diana Roettger, PhD, Head of Scientific and Medical Affairs and Imaging Clinical Research Expert at IAG Discusses Next Steps In…
Diana Roettger, PhD, Head of Scientific and Medical Affairs and Imaging Clinical Research Expert at IAG Discusses Machine Learning &…
Diana Roettger, PhD, Head of Scientific and Medical Affairs and Imaging Clinical Research Expert at IAG Discusses Advanced Imaging &…
Robert Motzer MD, board-certified medical oncologist of Memorial Sloan Kettering Cancer Center, discusses Progress In Advanced Kidney Cancer Treatment At…
Pascal Besman Chief Operating Officer at PharmaMar Discusses Differences Between NSCLC & SCLC. At ESMO Oncology Conference – Munich, Germany…
Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of…
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and…
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in…
Ricky Newton, CPA Director of Financial Services & Operations for Community Oncology Alliance describes the COAnalyzer Tool.
Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant…
Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant…
Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant…
Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center Discusses Integrative Medicine & Herbal Supplements. At…
Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center Discusses Immunotherapy Moving To Frontline. At Kidney…
Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center Discusses Gut Microbiome Upcoming Research. At Kidney…
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung…
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination…
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a…
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, talks about the collective organizational efforts to…
In this video, Dharmisha Chauhan, MPharm, of the Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of her…
Healthcare technologies and apps are important in supporting patients in their care, and can greatly benefit them in their treatment…
Kelly Baillie, of the NHS Greater Glasgow & Clyde, Glasgow, UK, presents the key findings from the Cancer Medicines Outcome…
At the 2018 British Oncology Pharmacy Association (BOPA) Annual Symposium, Simon Cheesman, MRPharmS, of University College London, London, UK, presented…
From the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Simon Cheesman, MRPharmS, from University College…
Oncology Pharmacists play an important role in the treatment and management of patients, but how visible are they to their…
Managing side effects can be an overwhelming experience for oncology patients, they may be unsure of the severity of their…
More than half of patients that undergo cancer treatment are estimated to have had at least one potential drug-drug interaction.…
The increased use of targeted therapies in oncology has introduced a range of new side effects. Emma Foreman, BPharma (Hons)…
A specialist workshop on non-medical prescribing was hosted at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, Birmingham, UK.…
The British Oncology Pharmacy Association (BOPA) has a number of exciting educational initiatives in the pipeline for 2019. BOPA committee…
Advanced therapy medicinal products (ATMPs) are a novel class of medicines offering treatment options for diseases that currently lack effective…
Catherine Oakley, PhD, of Guy’s and St Thomas NHS Foundation Trust, London, UK, highlights the benefits of the nurse and…
One of the topics discussed at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, was…
Non-medical prescribing is one of the important tasks undertaken by Oncology Pharmacists. Bryn Thomas, MPharm, from The Royal Marsden NHS…
While artificial intelligence (AI) has revolutionized healthcare by minimizing the element of human error, thus improving efficiency, limitations do still…
As chimeric antigen receptor (CAR) T-cell therapies are patient-specific, this novel treatment type poses unique challenges. From the British Oncology…
Substitutable Medical Apps, Reusable Technologies (SMART) apps have been developed to meet the need for responsiveness in healthcare IT. In…
Following the unfortunate IT failures at the Barts Health NHS Trust in 2017, which led to major issues in their…
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Analyzing Biological…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Kidney Cancer…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Rare Kidney…
Brian Shuch, MD Associate Professor of Urology at UCLA Discusses the Optimal Approach To Small Renal Mass. At Kidney Cancer…
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Renal Medullary…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Immunotherapy In…
Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.
Dr. Gerard Silvestri, Medical University of South Carolina, describes some of the typical presenting symptoms of lung cancer.
GRACE – Global Resource for Advancing Cancer Education Published on Feb 24, 2016 Dr. Gerard Silvestri, Medical University of South…
VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY discusses Why Use Systemic Therapy Before Surgery?. At Kidney Cancer Association National Patient…
VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY discusses Radiotherapy In Kidney Cancer. At Kidney Cancer Association National Patient and Caregiver…
VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY discusses EA8143 PROSPER RCC: Adjuvant Therapy with a Twist. At Kidney Cancer Association…
Chung-Han Lee, MD/PhD Memorial Sloan Kettering Cancer Center Discusses Objective Response Rate, Best Indicator? At Kidney Cancer Association National Patient…
Chung-Han Lee, MD/PhD Memorial Sloan Kettering Cancer Center Discusses Combinations in Kidney Cancer, Who Benefits? At Kidney Cancer Association National…
Chung-Han Lee, MD/PhD Memorial Sloan Kettering Cancer Center Discusses Combination, TKI, Immunotherapy Efficacy. At Kidney Cancer Association National Patient and…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology Discusses Von Hippel-Lindau Disease. At Kidney…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology Discusses Localized Recurrence Is Rare In…
Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the current outlook of Waldenströms macroglobulinemia (WM), from…
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, updates us at the European…
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, presents exciting results from clinical…
Approved monoclonal antibodies for multiple myeloma (MM) are currently available, yet there are still gaps to explore in this therapeutic…
What is the current treatment landscape for plasma cell leukemia and extramedullary disease in multiple myeloma (MM)? We spoke to…
The results of clinical trials are open to interpretation and are dependent upon a vast array of factors, including cohort…
Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses the updated analysis of the CASTOR trial (NCT02136134)…
Multiple myeloma (MM) therapy has evolved rapidly in recent years, and is showing no sign of slowing. Here, Kenneth Anderson,…
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Jesús San…
Heinz Ludwig, MD, PhD, from Wilhelminen Cancer Research Institute, Vienna, Austria, discusses treatment sequencing in multiple myeloma (MM). Dr Ludwig…
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Evangelos Terpos,…
Functional imaging techniques serve an essential role in diagnostics. Here, Elena Zamagni, MD, PhD, of the University of Bologna, Bologna,…
Annemiek Broyl, MD, PhD, from Erasmus Medical Center and University, Rotterdam, Netherlands, discusses how to treat high-risk multiple myeloma (MM).…
Alessandra Larocca, MD, PhD, of the University Hospital Città della Salute e della Scienza, Torino, Italy, discusses the importance of…
GRACE – Global Resource for Advancing Cancer Education Published on Feb 25, 2016 Dr. Gerard Silvestri, Medical University of South…
Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Sequencing Immunotherapies In Kidney…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Ipilimumab & Nivolumab Combo.…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses First Line Therapy In…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Combo Avelumab & Axitinib.…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Combinations In Anti VEGF…
Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses VEGF Inhibitors In Adjuvant…
Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses The Allure To The…
Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses ASSURE, S-TRAC, ATLAS, &…
Susan Demo, Ph.D Calithera Biosciences discusses Only 3% Of Cancer Patients Participate In Clinical Trials at Kidney Cancer Association National…
Mayer Fishman, MD PhD Dept. of GU Oncology Moffitt Cancer Center Dept. of Oncologic Sciences, USF Morsani College of Medicine…
Susan Demo, Ph.D Calithera Biosciences Discusses the Best Way For A Patient To Find A Clinical Trial. At Kidney Cancer…
Matt Campbell MD, MS Assistant Professor Department of Genitourinary Medical Oncology UT MD Anderson Cancer Center Discusses What Does PDL…
Matt Campbell MD, MS Assistant Professor Department of Genitourinary Medical Oncology UT MD Anderson Cancer Center Discusses When Should A…
The utilization of interim positron emission tomography (PET) imaging to guide therapeutic decisions has the potential to further individualize therapy,…
Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant…
Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of…
Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of…
Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of…
Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of…
Brian Shuch, MD Associate Professor of Urology at UCLA Discusses the Risk Of New Tumor Developing at Kidney Cancer Association…
Brian Shuch, MD Associate Professor of Urology at UCLA Discusses the Treatment Of The Incidental Renal Mass at Kidney Cancer…
E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health discusses Surgery in kidney cancer at…
E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health Discusses the Higher Risk Of Occurrence…
E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health discusses the Complex Surgery Locally Advanced…
Steven Rosen, MD, from the City of Hope, Duarte, CA, discusses the remarkable quantity and quality of information on blood…
The field of blood cancer therapeutics has seen enormous progression. Here, Steven Rosen, MD, from the City of Hope, Duarte,…
Speaking from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France, Bianca Santomasso, MD, PhD, of…
Pablo Ortiz, MD, PhD, of the University Hospital 12 of October, Madrid, Spain, speaks at the European Organisation for the…
Pablo Ortiz, MD, PhD, of the University Hospital 12 of October, Madrid, Spain, speaks at the European Organisation for the…
Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, discusses the future of checkpoint inhibitors in…
Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, speaks at the European Organisation for the…
Topical alkylating agents have proven beneficial in treating patients with mycosis fungoides (MF). Here, Martine Bagot, MD, PhD, of Saint…
Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, discusses the exciting new approval of the antibody mogumulizumab for…
Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, speaks at the European Organisation for the Research and Treatment…
Maintenance therapy options for cutaneous T-cell lymphomas could be improved. Here, Rudolf Stadler, MD, PhD, of the University Medical Center…
An accurate and optimized clinical scoring system is essential for the staging and management of cutaneous T-cell lymphoma. Here, Pietro…
Establishing a registry and prognostic index for mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), and Sézary…
CD47 has been found to be present on leukemic stem cells, but not on normal hematopoietic stem cells, offering an…
Our understanding of stem cells has improved exponentially since their discovery, transforming our treatment of hematological malignancies and other diseases.…
A novel CD47-blocking checkpoint inhibitor has shown promising interim results in a multicenter Phase I trail for relapsed/refractory mycosis fungoides…
From the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting held in Nice, France, Francine Foss, MD, of Yale University…
Precision medicine is improving outcomes, toxicity and disease management in trials and routine clinical practice. Anas Younes, MD, from the…
Cell-based therapies are an exciting area across the board in oncology. Here, our experts discuss the use of cellular therapy…
Viruses such Epstein-Barr virus (EBV) and HIV have been aetiologically linked to a significant number of lymphoproliferative diseases. In this…
While novel FLT3 inhibitors have been, or will be, approved for use as single agents in the treatment of acute…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the…
Venetoclax in combination with low intensity chemotherapy for acute myeloid leukemia (AML) in the frontline setting, which although currently under…
Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses clinical trials testing new drugs on patients with relapsed Hodgkin…
With the the field of molecular diagnostics rapidly advancing, the demand for prognostic and diagnostic molecular information on myelodysplastic syndrome…
Torsten Haferlach, MD, PhD, of the Munich Leukaemia laboratory, Munich, Germany, highlights the rapidly expanding field of molecular diagnostics, moving…
Knowledge of the molecular background of myelodysplastic syndrome (MDS) has been greatly advanced by developments in techniques such as next-generation…
The mechanism for the previously unknown occurrence of thrombocytopenia and neutropenia in patients with myeloma treated with immunomodulatory drugs (IMiDs)…